Landing in the company's first year, the medical device company continued the high growth trend.

"Pharmaceutical Network Corporate News" July 22, 2019, heart vein medical officially landed on the boardNow, a year later, what kind of transcripts has the medical device company handed over? On March 30, Heart Medical reported that in 2019, the company achieved operating income of 334 million yuan, up 44.39 percent year-on-year, and net profit of 142 million yuan, up 56.38 percent year-on-yearAnd the company is continuing the high growth trendRecently, Heart Medical released its 2020 half-year results forecast, which is expected to achieve net profit attributable to the owner of the parent company of 1.18 to 123 million yuan, an increase of 38.80 percent to 44.68 percent year-on-yearPublic information shows that cardiovascular medicine is mainly engaged in aortic and peripheral vascular intervention medical device research and development, production and salesIts main products include thoracic aortic stent system, abdominal aortic stent system, intraoperative stent system, peripheral artery intervention productsAt present, cardio-pulmons medicine is in the medical device industry is in a rapid development stageData show that in 2018, China's medical device market size is about 530.4 billion yuan, up 19.86 percent year-on-yearThe medical device industry is a strategic emerging industry supported by China's key support, with broad prospects for developmentEspecially since 2020, the medical device industry by the policy, market influence, has been rapid developmentIn terms of cardiovascular interventional medical device products, with 2018 surgery volume statistics, cardiovascular medicine in the domestic market share in the field ranked second, after imported products Medtronic, in the domestic brand market share ranking, market share of about 26%In 2019, the revenue of the aortic stent products of cardiopulmonary medicine was RMB276 million, up 46.64 percent year-on-year, accounting for 85.33 percent of the total revenueThe company expects continued high results this yearIn the first half of the year, it is expected to achieve net profit of RMB118 million to RMB123 million, up 38.80 percent to 44.68 percent YoY, while net profit from non-deducted profit is RMB108 million to RMB113 million, up 40.44 percent to 46.94 percent YoYIn response to the reasons for the rapid growth of the company, the company said that the company's business gradually resumed in the second quarter, sales revenue returned to a good growth trendAmong them, the Company's Castor branch-type aortic mulch stent and delivery system, which was listed in the second half of 2017, continued to grow rapidly in the first half of this year, while new products such as Minos aortic aortic mulch stents and conveyor systems, Reewarm PTX drug balloon expansion catheters were steadily advancing the tender admission process and gradually beginning to contribute to revenue growth during the reporting periodIn addition to the growth in performance, heart care research and development investment in recent years has also been increasing Data show that in the three years 2016-2018, heart-based medical research and development investment (including capitalized development expenditure) as a proportion of operating income for the year as high as 26.94 percent, always at a high level among comparable companies in the same industry In addition, in 2019, heart-to-heart medical research and development investment increased by 25.14% to 6069.01 million yuan, accounting for 18.19% of revenue At present, cardiology medicine has 2 thoracic aortic stents, 3 abdominal aortic stents, 1 intraoperative stent, and a number of innovative products are expected to be available in the next 2-3 years, is expected to maintain the company's dominant position in the field It is also worth mentioning that on April 26 this year, The Reewarm PTX drug balloon dilating catheter, developed by Cardios Medical, was awarded the Class III Medical Device Certificate by the State Drug Administration The industry believes that with the launch of this year's drug balloon, the peripheral field or will enter a rapid growth, the future is expected to provide a power for the company's medium- and long-term development